Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia

Stem Cell Research and Therapy

Volumn 3, Issue 4, 2012, Pages

  Liew, Aaron ^a   O'Brien, Timothy ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SCATTER FACTOR; VASCULOTROPIN;

ANTIANGIOGENIC GENE THERAPY; BUERGER DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CRITICAL LIMB ISCHEMIA; DIABETIC FOOT; DRUG SAFETY; ENDOTHELIUM; FEASIBILITY STUDY; HEALTH CARE NEED; HINDLIMB; HUMAN; IMMUNOMODULATION; INTERMETHOD COMPARISON; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MUSCLE DEVELOPMENT; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PATIENT SAFETY; PATIENT SELECTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; THERAPY EFFECT; ANIMAL; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); CYTOLOGY; DRUG SCREENING; GENE THERAPY; ISCHEMIA; MESENCHYMAL STROMA CELL;

ANIMALIA;

ANIMALS; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GENETIC THERAPY; HUMANS; IMMUNOMODULATION; ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PARACRINE COMMUNICATION;

EID: 84864777298     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt119     Document Type: Review

References (92)

1. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, J Vasc Surg 2007 45 Suppl S 5 67 17223489
2. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, Steg G, Bhatt DL, Hirsch AT, Circ Cardiovasc Qual Outcomes 2010 3 642 651 10.1161/CIRCOUTCOMES.109.930735 20940249
3. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, et al. Circulation 2006 113 463 654 16549646
4. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR, Diabetes Care 2006 29 877 882 10.2337/diacare.29.04.06.dc05-2018 16567831 (Pubitemid 44115310)
5. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH, Ann Intern Med 2004 141 421 431 15381515
6. ClinicalTrials.gov homepage. http://www.clinicaltrials.gov
7. Gene therapy in vascular disease. Sedighiani F, Nikol S, Surgeon 2011 9 326 335 10.1016/j.surge.2011.05.003 22041646
8. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E, Lancet 2011 377 1929 1937 10.1016/S0140-6736(11)60394-2 21621834
9. Mesenchymal stem cells: clinical applications and biological characterization. Barry FP, Murphy JM, Int J Biochem Cell Biol 2004 36 568 584 10.1016/j.biocel.2003.11.001 15010324 (Pubitemid 38324589)
10. Therapeutic benefit of human umbilical cord derived mesenchymal stromal cells in intracerebral hemorrhage rat: implications of anti-inflammation and angiogenesis. Liao W, Zhong J, Yu J, Xie J, Liu Y, Du L, Yang S, Liu P, Xu J, Wang J, Han Z, Han ZC, Cell Physiol Biochem 2009 24 307 316 10.1159/000233255 19710545
11. Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, Mishima K, Iwasaki K, Fujiwara M, Kitamura S, Nagaya N, Ikeda T, Stem Cells 2008 26 2625 2633 10.1634/stemcells. 2008-0236 18669910
12. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Iwase T, Nagaya N, Fujii T, Itoh T, Murakami S, Matsumoto T, Kangawa K, Kitamura S, Cardiovasc Res 2005 66 543 551 10.1016/j.cardiores.2005.02.006 15914119 (Pubitemid 40725766)
13. Angiogenic effects despite limited cell survival of bone marrow-derived mesenchymal stem cells under ischemia. Hoffmann J, Glassford AJ, Doyle TC, Robbins RC, Schrepfer S, Pelletier MP, Thorac Cardiovasc Surg 2010 58 136 142 10.1055/s-0029-1240758 20379963
14. Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. Gruenloh W, Kambal A, Sondergaard C, McGee J, Nacey C, Kalomoiris S, Pepper K, Olson S, Fierro F, Nolta JA, Tissue Eng Part A 2011 17 1517 1525 10.1089/ten.tea.2010.0460 21275830
15. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A, J Neuroimmunol 2010 227 185 189 10.1016/j.jneuroim.2010.07.013 20728948
16. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, Lam FF, Kang S, Xia JC, Lai WH, Au KW, Chow YY, Siu CW, Lee CN, Tse HF, Circulation 2010 121 1113 1123 10.1161/CIRCULATIONAHA.109.898312 20176987
17. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J, Cell Physiol Biochem 2007 20 867 876 10.1159/000110447 17982269 (Pubitemid 350059730)
18. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Gruber R, Kandler B, Holzmann P, Vogele-Kadletz M, Losert U, Fischer MB, Watzek G, Tissue Eng 2005 11 896 903 10.1089/ten.2005.11.896 15998229 (Pubitemid 40960792)
19. Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats. Wang CY, Yang HB, Hsu HS, Chen LL, Tsai CC, Tsai KS, Yew TL, Kao YH, Hung SC, J Tissue Eng Regen Med 2012 6 559 569 10.1002/term.461 21916015
20. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, March KL, Circulation 2004 109 1292 1298 10.1161/01.CIR.0000121425.42966.F1 14993122 (Pubitemid 38372789)
21. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE, Circ Res 2004 94 678 685 10.1161/01.RES.0000118601.37875.AC 14739163 (Pubitemid 38387752)
22. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE, Circulation 2004 109 1543 1549 10.1161/01.CIR.0000124062.31102.57 15023891 (Pubitemid 38420184)
23. Mesenchymal cells stimulate capillary morphogenesis via distinct proteolytic mechanisms. Ghajar CM, Kachgal S, Kniazeva E, Mori H, Costes SV, George SC, Putnam AJ, Exp Cell Res 2010 316 813 825 10.1016/j.yexcr.2010.01.013 20067788
24. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, Salto-Tellez M, Timmers L, Lee CN, El Oakley RM, Pasterkamp G, de Kleijn DP, Lim SK, Stem Cell Res 2010 4 214 222 10.1016/j.scr.2009.12.003 20138817
25. Mesenchymal stem cells enhance angiogenesis in mechanically viable prevascularized tissues via early matrix metalloproteinase upregulation. Ghajar CM, Blevins KS, Hughes CC, George SC, Putnam AJ, Tissue Eng 2006 12 2875 2888 10.1089/ten.2006.12.2875 17518656 (Pubitemid 46141254)
26. Influence of adult mesenchymal stem cells on in vitro vascular formation. Sorrell JM, Baber MA, Caplan AI, Tissue Eng Part A 2009 15 1751 1761 10.1089/ten.tea.2008.0254 19196139
27. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ, Cell Stem Cell 2009 5 54 63 10.1016/j.stem.2009.05. 003 19570514
28. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, Beilhack A, Negrin R, Reisner Y, Stem Cells 2009 27 2865 2874 10.1002/stem.217 19750539
29. Safety and biodistribution profile of placental-derived mesenchymal stromal cells (PLX-PAD) following intramuscular delivery. Ramot Y, Meiron M, Toren A, Steiner M, Nyska A, Toxicol Pathol 2009 37 606 616 10.1177/ 0192623309338383 19478280
30. Myogenic properties of human mesenchymal stem cells derived from three different sources. de la Garza-Rodea AS, van der Velde-van Dijke L, Boersma H, Goncalves MA, van Bekkum DW, de Vries AA, Knaan-Shanzer S, Cell Transplant 2012 21 153 173 21669036
31. Local injections of adipose-derived mesenchymal stem cells modulate inflammation and increase angiogenesis ameliorating the dystrophic phenotype in dystrophin-deficient skeletal muscle. da Justa Pinheiro CH, de Queiroz JC, Guimaraes-Ferreira L, Vitzel KF, Nachbar RT, de Sousa LG, de Souza-Jr AL, Nunes MT, Curi R, Stem Cell Rev 2012 8 363 374 10.1007/s12015-011-9304-0 21874281
32. Hypoxia preconditioned mesenchymal stem cells improve vascular and skeletal muscle fiber regeneration after ischemia through a Wnt4-dependent pathway. Leroux L, Descamps B, Tojais NF, Séguy B, Oses P, Moreau C, Daret D, Ivanovic Z, Boiron JM, Lamazière JM, Dufourcq P, Couffinhal T, Dupla C, Mol Ther 2010 18 1545 1552 10.1038/mt.2010.108 20551912
33. The stimulation of the cardiac differentiation of mesenchymal stem cells in tissue constructs that mimic myocardium structure and biomechanics. Guan J, Wang F, Li Z, Chen J, Guo X, Liao J, Moldovan NI, Biomaterials 2011 32 5568 5580 10.1016/j.biomaterials.2011.04.038 21570113
34. Unsorted human adipose tissue-derived stem cells promote angiogenesis and myogenesis in murine ischemic hindlimb model. Kang Y, Park C, Kim D, Seong CM, Kwon K, Choi C, Microvasc Res 2010 80 310 316 10.1016/j.mvr.2010.05.006 20510252
35. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs). Gong Z, Niklason LE, FASEB J 2008 22 1635 1648 10.1096/fj.07-087924 18199698 (Pubitemid 351811442)
36. Readily available tissue-engineered vascular grafts. Dahl SL, Kypson AP, Lawson JH, Blum JL, Strader JT, Li Y, Manson RJ, Tente WE, DiBernardo L, Hensley MT, Carter R, Williams TP, Prichard HL, Dey MS, Begelman KG, Niklason LE, Sci Transl Med 2011 3 68ra9 10.1126/scitranslmed.3001426 21289273
37. Differentiation of human bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue engineering. Tian H, Bharadwaj S, Liu Y, Ma PX, Atala A, Zhang Y, Tissue Eng Part A 2010 16 1769 1779 10.1089/ten.tea.2009.0625 20020816
38. Endothelial differentiation of amniotic fluid-derived stem cells: synergism of biochemical and shear force stimuli. Zhang P, Baxter J, Vinod K, Tulenko TN, Di Muzio PJ, Stem Cells Dev 2009 18 1299 1308 10.1089/scd.2008.0331 19508152
39. Angiogenic potential of human dental pulp stromal (stem) cells. Marchionni C, Bonsi L, Alviano F, Lanzoni G, Di Tullio A, Costa R, Montanari M, Tazzari PL, Ricci F, Pasquinelli G, Orrico C, Grossi A, Prati C, Bagnara GP, Int J Immunopathol Pharmacol 2009 22 699 706 19822086
40. Endothelial differentiation of Wharton's jelly derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Chen MY, Lie PC, Li ZL, Wei X, Exp Hematol 2009 37 629 640 10.1016/j.exphem.2009.02.003 19375653
41. Shear stress induces endothelial differentiation from a murine embryonic mesenchymal progenitor cell line. Wang H, Riha GM, Yan S, Li M, Chai H, Yang H, Yao Q, Chen C, Arterioscler Thromb Vasc Biol 2005 25 1817 1823 10.1161/01.ATV.0000175840.90510.a8 15994439 (Pubitemid 41243448)
42. Mesenchymal stem cells overexpressing ephrin-B2 rapidly adopt an early endothelial phenotype with simultaneous reduction of osteogenic potential. Duffy GP, D'Arcy S, Ahsan T, Nerem RM, O'Brien T, Barry F, Tissue Eng Part A 2010 16 2755 2768 10.1089/ten.tea.2009.0623 20491587
43. Characterization of endothelial-like cells derived from human mesenchymal stem cells. Liu JW, Dunoyer-Geindre S, Serre-Beinier V, Mai G, Lambert JF, Fish RJ, Pernod G, Buehler L, Bounameaux H, Kruithof EK, J Thromb Haemost 2007 5 826 834 10.1111/j.1538-7836.2007.02381.x 17229052 (Pubitemid 46563584)
44. Bone marrow-derived mesenchymal stem cells promote angiogenic processes in a time- and dose-dependent manner in vitro. Duffy GP, Ahsan T, O'Brien T, Barry F, Nerem RM, Tissue Eng Part A 2009 15 2459 2470 10.1089/ten.tea.2008.0341 19327020
45. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Amin AH, Abd Elmageed ZY, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, Matrougui K, Lab Invest 2010 90 985 996 10.1038/labinvest.2010.86 20440273
46. Dynamics of bone marrow-derived endothelial progenitor cell/mesenchymal stem cell interaction in co-culture and its implications in angiogenesis. Aguirre A, Planell JA, Engel E, Biochem Biophys Res Commun 2010 400 284 291 10.1016/j.bbrc.2010.08.073 20732306
47. Human mesenchymal stem cells express vascular cell phenotypes upon interaction with endothelial cell matrix. Lozito TP, Kuo CK, Taboas JM, Tuan RS, J Cell Biochem 2009 107 714 722 10.1002/jcb.22167 19415687
48. Secreted frizzled-related protein-1 enhances mesenchymal stem cell function in angiogenesis and contributes to neovessel maturation. Dufourcq P, Descamps B, Tojais NF, Leroux L, Oses P, Daret D, Moreau C, Lamaziere JM, Couffinhal T, Duplaa C, Stem Cells 2008 26 2991 3001 10.1634/stemcells.2008-0372 18757297
49. Immunological aspects of allogeneic mesenchymal stem cell therapies. Griffin MD, Ritter T, Mahon BP, Hum Gene Ther 2010 21 1641 1655 10.1089/hum.2010.156 20718666
50. Allogeneic administration of fetal membrane-derived mesenchymal stem cells attenuates acute myocarditis in rats. Ishikane S, Yamahara K, Sada M, Harada K, Kodama M, Ishibashi-Ueda H, Hayakawa K, Mishima K, Iwasaki K, Fujiwara M, Kangawa K, Ikeda T, J Mol Cell Cardiol 2010 49 753 761 10.1016/j.yjmcc.2010. 07.019 20692268
51. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM, Cytotherapy 2009 11 427 434 10.1080/14653240902849762 19526389
52. Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/beta-catenin signaling. Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, Redell JB, Grill R, Matsuo Y, Guha S, Cox CS, Reitz MS, Holcomb JB, Dash PK, Stem Cells Dev 2011 20 89 101 10.1089/scd.2010.0013 20446815
53. CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells. Wang D, Chen K, Du WT, Han ZB, Ren H, Chi Y, Yang SG, Bayard F, Zhu D, Han ZC, Exp Cell Res 2010 316 2414 2423 10.1016/j.yexcr.2010. 04.018 20420825
54. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Hu X, Wang J, Chen J, Luo R, He A, Xie X, Li J, Eur J Cardiothorac Surg 2007 31 438 443 10.1016/j.ejcts.2006.11.057 17239611 (Pubitemid 46329387)
55. Optimal time for mesenchymal stem cell transplantation in rats with myocardial infarction. Jiang CY, Gui C, He AN, Hu XY, Chen J, Jiang Y, Wang JA, J Zhejiang Univ Sci B 2008 9 630 637 10.1631/jzus.B0820004 18763313
56. Mesenchymal stem cell therapy: two steps forward, one step back. Ankrum J, Karp JM, Trends Mol Med 2010 16 203 209 10.1016/j.molmed.2010.02.005 20335067
57. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K, Kuroda R, Kurosaka M, Yoshiya S, Hattori K, Ohgushi H, J Tissue Eng Regen Med 2011 5 146 150 10.1002/term.299 20603892
58. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S, Arch Neurol 2010 67 1187 1194 10.1001/archneurol.2010.248 20937945
59. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY, Stem Cells 2010 28 1099 1106 10.1002/stem.430 20506226
60. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW, Gut 2010 59 1662 1669 10.1136/gut.2010.215152 20921206
61. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W, J Am Coll Cardiol 2009 54 2277 2286 10.1016/j.jacc.2009.06.055 19958962
62. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Rosova I, Dao M, Capoccia B, Link D, Nolta JA, Stem Cells 2008 26 2173 2182 10.1634/stemcells.2007-1104 18511601
63. shRNA-mediated decreases in c-Met levels affect the differentiation potential of human mesenchymal stem cells and reduce their capacity for tissue repair. Rosova I, Link D, Nolta JA, Tissue Eng Part A 2010 16 2627 2639 10.1089/ten.tea.2009.0363 20367286
64. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. Nakagami H, Morishita R, Maeda K, Kikuchi Y, Ogihara T, Kaneda Y, J Atheroscler Thromb 2006 13 77 81 10.5551/jat.13.77 16733294
65. Zinc supplementation results in improved therapeutic potential of bone marrow-derived mesenchymal stromal cells in a mouse ischemic limb model. Zhang D, Li Y, Zhu T, Zhang F, Yang Z, Miao D, Cytotherapy 2011 13 156 164 10.3109/14653249.2010.512633 20839997
66. Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia. Zhang Y, Zhang R, Li Y, He G, Zhang D, Zhang F, Mol Biol Rep 2012 39 285 293 10.1007/s11033-011-0737-y 21553056
67. Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation. Li Y, Zhang D, Zhang Y, He G, Zhang F, J Biomed Sci 2010 17 75 10.1186/1423-0127-17-75 20846454
68. Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. Ishii M, Numaguchi Y, Okumura K, Kubota R, Ma X, Murakami R, Naruse K, Murohara T, Atherosclerosis 2009 206 109 118 10.1016/j.atherosclerosis.2009.02.023 19344900
69. Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau AM, Pyszniak A, Carrier E, Ichim TE, Riordan NH, J Transl Med 2008 6 45 10.1186/1479-5876-6-45 18713449
70. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Al-Khaldi A, Al-Sabti H, Galipeau J, Lachapelle K, Ann Thorac Surg 2003 75 204 209 10.1016/S0003-4975(02) 04291-1 12537217 (Pubitemid 36099048)
71. Transplantation of sendai viral angiopoietin-1-modified mesenchymal stem cells for ischemic limb disease. Piao W, Wang H, Inoue M, Hasegawa M, Hamada H, Huang J, Angiogenesis 2010 13 203 210 10.1007/s10456-010-9169-x 20458615
72. Transplantation of MSCs in combination with netrin-1 improves neoangiogenesis in a rat model of hind limb ischemia. Li Q, Yao D, Ma J, Zhu J, Xu X, Ren Y, Ding X, Mao X, J Surg Res 2011 166 162 169 10.1016/j.jss.2009.08. 031 20070983
73. Novel culture system of mesenchymal stromal cells from human subcutaneous adipose tissue. Iwashima S, Ozaki T, Maruyama S, Saka Y, Kobori M, Omae K, Yamaguchi H, Niimi T, Toriyama K, Kamei Y, Torii S, Murohara T, Yuzawa Y, Kitagawa Y, Matsuo S, Stem Cells Dev 2009 18 533 543 10.1089/scd.2008.0358 19055360
74. Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Moon MH, Kim SY, Kim YJ, Kim SJ, Lee JB, Bae YC, Sung SM, Jung JS, Cell Physiol Biochem 2006 17 279 290 10.1159/000094140 16791003 (Pubitemid 43946282)
75. Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells. Bhang SH, Cho SW, La WG, Lee TJ, Yang HS, Sun AY, Baek SH, Rhie JW, Kim BS, Biomaterials 2011 32 2734 2747 10.1016/j. biomaterials.2010.12.035 21262528
76. Locally delivered growth factor enhances the angiogenic efficacy of adipose-derived stromal cells transplanted to ischemic limbs. Bhang SH, Cho SW, Lim JM, Kang JM, Lee TJ, Yang HS, Song YS, Park MH, Kim HS, Yoo KJ, Jang Y, Langer R, Anderson DG, Kim BS, Stem Cells 2009 27 1976 1986 10.1002/stem.115 19544425
77. The role of chemokines in proangiogenic action induced by human adipose tissue-derived mesenchymal stem cells in the murine model of hindlimb ischemia. Cho HH, Kim YJ, Kim JT, Song JS, Shin KK, Bae YC, Jung JS, Cell Physiol Biochem 2009 24 511 518 10.1159/000257495 19910691
78. Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model. Laurila JP, Laatikainen L, Castellone MD, Trivedi P, Heikkila J, Hinkkanen A, Hematti P, Laukkanen MO, Cytotherapy 2009 11 726 737 10.3109/14653240903067299 19878059
79. Neovascularization in a mouse model via stem cells derived from human fetal amniotic membranes. Kim HG, Choi OH, Heart Vessels 2011 26 196 205 10.1007/s00380-010-0064-6 21188388
80. A potential pro-angiogenic cell therapy with human placenta-derived mesenchymal cells. Nishishita T, Ouchi K, Zhang X, Inoue M, Inazawa T, Yoshiura K, Kuwabara K, Nakaoka T, Watanabe N, Igura K, Takahashi TA, Yamashita N, Biochem Biophys Res Commun 2004 325 24 31 10.1016/j.bbrc.2004.10.003 15522196 (Pubitemid 39441156)
81. Delivery of fibroblast growth factor 2 enhances the viability of cord blood-derived mesenchymal stem cells transplanted to ischemic limbs. Bhang SH, Lee TJ, La WG, Kim DI, Kim BS, J Biosci Bioeng 2011 111 584 589 10.1016/j.jbiosc.2011.01.003 21388874
82. Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model. Kim SW, Han H, Chae GT, Lee SH, Bo S, Yoon JH, Lee YS, Lee KS, Park HK, Kang KS, Stem Cells 2006 24 1620 1626 10.1634/stemcells.2005-0365 16497946 (Pubitemid 44464680)
83. Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Koponen JK, Kekarainen T, S EH, Laitinen A, Nystedt J, Laine J, Yla-Herttuala S, Mol Ther 2007 15 2172 2177 10.1038/sj.mt.6300302 17878901 (Pubitemid 350148934)
84. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC, Rejuvenation Res 2009 12 359 366 10.1089/rej.2009.0872 19929258
85. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Guiducci S, Porta F, Saccardi R, Guidi S, Ibba-Manneschi L, Manetti M, Mazzanti B, Dal Pozzo S, Milia AF, Bellando-Randone S, Miniati I, Fiori G, Fontana R, Amanzi L, Braschi F, Bosi A, Matucci-Cerinic M, Ann Intern Med 2010 153 650 654 21079220
86. Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Lasala GP, Silva JA, Gardner PA, Minguell JJ, Angiology 2010 61 551 556 10.1177/0003319710364213 20498146
87. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. Lasala GP, Silva JA, Minguell JJ, J Thorac Cardiovasc Surg 2012 144 377 382 10.1016/j.jtcvs.2011.08. 053 22079876
88. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S, Diabetes Res Clin Pract 2011 92 26 36 10.1016/j.diabres.2010.12.010 21216483
89. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia. Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, Park JH, Lee SY, Kim SP, Kim YD, Chung SW, Bae YC, Shin YB, Kim JI, Jung JS, Circ J 2012 76 1750 1760 22498564
90. Stempeutics announces clinical trial outcome of India's first stem cell product stempeucel. http://www.stempeutics.com/html/Article%201.pdf
91. Pluristem Therapeutics, Inc. (PSTI)-Buy. http://www.pluristem.com/ CPY155053[1].pdf
92. Understanding objective performance goals for critical limb ischemia trials. Conte MS, Semin Vasc Surg 2010 23 129 137 10.1053/j.semvascsurg.2010.06. 001 20826289